

					

						November 25, 2017 - By Peter Erickson
 The stock of Sanofi (NYSE:SNY) registered an increase of 3.82% in short interest. SNY’s total short interest was 1.95 million shares in November as published by FINRA. Its up 3.82% from 1.88M shares, reported previously. With 1.54M shares average volume, it will take short sellers 1 days to cover their SNY’s short positions. The short interest to Sanofi’s float is 0.09%. The stock increased 1.61% or $0.73 on November 24, reaching $46.1. About 523,759 shares traded. Sanofi SA (ADR) (NYSE:SNY) has risen 26.96% since November 25, 2016 and is uptrending. It has outperformed by 10.26% the S&P500.Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The company has market cap of $118.59 billion. The Company’s divisions are Pharmaceuticals, Human Vaccines , and Other. It has a 21.4 P/E ratio. The Pharmaceuticals segment comprises the commercial activities of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.Among 11 analysts covering Sanofi-aventis Sa (NYSE:SNY), 2 have Buy rating, 0 Sell and 9 Hold. Therefore 18% are positive. Sanofi-aventis Sa has $56 highest and $50.0 lowest target. $52.67’s average target is 14.25% above currents $46.1 stock price. Sanofi-aventis Sa had 20 analyst reports since October 15, 2015 according to SRatingsIntel. The firm earned “Neutral” rating on Friday, September 23 by Piper Jaffray. The firm earned “Sell” rating on Friday, March 31 by JP Morgan. The rating was initiated by Goldman Sachs with “Neutral” on Monday, November 7. The company was downgraded on Thursday, May 11 by Berenberg. As per Friday, October 13, the company rating was maintained by Cowen & Co. The firm earned “Buy” rating on Thursday, April 6 by Argus Research. The stock of Sanofi SA (ADR) (NYSE:SNY) has “Mkt Perform” rating given on Monday, November 9 by Bernstein. The rating was downgraded by HSBC on Tuesday, May 3 to “Hold”. The company was upgraded on Tuesday, September 13 by BNP Paribas. BNP Paribas downgraded Sanofi SA (ADR) (NYSE:SNY) on Thursday, December 10 to “Underperform” rating.More recent Sanofi SA (ADR) (NYSE:SNY) news were published by: Benzinga.com which released: “The Pullback In Sanofi Is A Buying Opportunity, Says Argus” on September 01, 2017. Also Investorplace.com published the news titled: “Think Sanofi SA (ADR) (SNY) Stock When You Think Big Pharma” on December 09, 2016. Investorplace.com‘s news article titled: “5 Reasons Why Sanofi SA (ADR) (SNY) is a Good Stock to Buy Now” with publication date: April 12, 2017 was also an interesting one.Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.



(adsbygoogle = window.adsbygoogle || []).push({});
TRADE IDEAS REVIEW – IS THIS THE BEST STOCK SCANNER?

Trade Ideas is arguably one of the top scanning tools available on the market right

Trade Ideas Pro helps traders find the best setups in the market right NOW

Scottrade and E*TRADE license Trade Ideas proprietary technology for their premium trading platforms. We have fully automated trading available through Lightspeed and Interactive Brokers.Trade Ideas is the BEST Tool for Scanning. I would be LOST without Trade ideas. Ross Cameron – Warrior Trading